|
CTR9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.2896021724157E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.58499999791673E-08 |
| Normal-vs-Stage2 |
1.603380E-04 |
| Normal-vs-Stage3 |
5.78820325003448E-11 |
| Normal-vs-Stage4 |
1.64279700953784E-11 |
| Stage1-vs-Stage2 |
5.457200E-01 |
| Stage1-vs-Stage3 |
2.381600E-02 |
| Stage1-vs-Stage4 |
2.297800E-03 |
| Stage2-vs-Stage3 |
3.838100E-02 |
| Stage2-vs-Stage4 |
7.696700E-03 |
| Stage3-vs-Stage4 |
4.010600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.34929853348831E-11 |
| Normal-vs-AfricanAmerican |
3.016800E-04 |
| Normal-vs-Asian |
3.50239999999946E-05 |
| Caucasian-vs-AfricanAmerican |
6.152000E-01 |
| Caucasian-vs-Asian |
3.127600E-01 |
| AfricanAmerican-vs-Asian |
8.291400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.59909887950971E-12 |
| Normal-vs-Female |
3.02610003721782E-09 |
| Male-vs-Female |
1.788010E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.09000000025894E-07 |
| Normal-vs-Age(41-60Yrs) |
3.19969994944103E-09 |
| Normal-vs-Age(61-80Yrs) |
5.30959720634883E-11 |
| Normal-vs-Age(81-100Yrs) |
3.432200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.382800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.332100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.273200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.919790E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.295800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.916200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.431900E-02 |
| Classical-VS-Follicular |
7.480400E-02 |
| Classical-VS-Other |
1.553580E-01 |
| Classical-VS-Normal |
1.6407999958723E-08 |
| Tall-VS-Follicular |
2.890000E-01 |
| Tall-VS-Other |
7.681600E-01 |
| Tall-VS-Normal |
1.95320000173638E-08 |
| Follicular-VS-Other |
4.745400E-01 |
| Follicular-VS-Normal |
3.13200000379155E-08 |
| Other-VS-Normal |
7.390600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.67630001388386E-09 |
| Normal-vs-N1 |
1.36179956200522E-10 |
| N0-vs-N1 |
3.390100E-02 |
|
|
